Pleomorphic rhabdomyosarcoma
MONDO:0017386An aggressive malignant mesenchymal neoplasm with skeletal muscle differentiation, occurring in adults and rarely in children. The tumor is characterized by the presence of bizarre round, spindle, and polygonal cells. Clinical presentation includes a rapidly enlarging painful mass usually of the lower extremities.
Also known as: pleomorphic rhabdomyosarcoma
2818 clinical trials for this condition and its sub-types, 7 tagged with Pleomorphic rhabdomyosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pleomorphic rhabdomyosarcoma
-
Adult pleomorphic rhabdomyosarcoma 0 trials
-
New combo therapy aims to shrink sarcomas
Disease control Recruiting nowThis early-stage trial tests whether giving a targeted drug (palbociclib) before immunotherapy (pembrolizumab) is safe and can help shrink tumors in people with certain soft tissue sarcomas. About 8 participants will receive the combination. The main goal is to check for side eff…
Phase 1 • Sponsor: John Rieth • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Proton beam boost: new hope for inoperable sarcomas?
Disease control Recruiting nowThis study tests whether a higher dose of proton radiation can better control inoperable soft tissue sarcomas without increasing side effects. Forty adults with these rare tumors will receive targeted radiation over 4 weeks. Researchers will also look at blood and imaging markers…
Phase 2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New 3-Week radiation plan aims to cut side effects for sarcoma patients
Disease control Recruiting nowThis study tests whether a personalized 3-week course of proton radiation before surgery for soft tissue sarcoma can reduce long-term side effects compared to standard X-ray radiation. About 110 adults in Norway will receive either proton or X-ray therapy, chosen individually for…
Phase 2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for sarcoma patients: immunotherapy plus chemo shows promise
Disease control Recruiting nowThis study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC